 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sagimet Biosciences Inc. Series A (NASDAQ:SGMT  Get Free Report) and BeiGene (NASDAQ:BGNE  Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, ...

Sagimet Biosciences Inc. Series A (NASDAQ:SGMT) & BeiGene (NASDAQ:BGNE) Head to Head Contrast

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ginkgo Bioworks Holdings (DNA Research Report) and... Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ginkgo Bioworks Holdings (DNA Research Report) and ...

Analysts Are Bullish on Top Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Sagimet Biosciences, Inc. Class A (SGMT)

Sagimet Biosciences GAAP EPS of -$35.80

Completed upsized initial public offering raising $96.4 million in gross proceeds Presented positive data at EASL Congress 2023 from the planned interim readout of the Phase 2b FASCINATE-2 trial in NASH showing denifanstat was well-tolerated and met week 26 liver fat response endpoint On track to ...

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences Inc. Series As (NASDAQ:SGMT  Get Free Report) quiet period is set to end on Wednesday, August 23rd. Sagimet Biosciences Inc. Series A had issued 5,312,500 shares in its public offering on July 14th. The total size of the offering was $85,000,000 based on an initial ...

Sagimet Biosciences Inc. Series A's (NASDAQ:SGMT) Quiet Period Will End  on August 23rd

SAN MATEO, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced the closing of the sale of an additional 714,272 shares of ...

Sagimet Biosciences Announces Closing of Underwriters' Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering

Research analysts at The Goldman Sachs Group started coverage on shares of Sagimet Biosciences Inc. Series A (NASDAQ:SGMT Get Free Report) in a research note issued on Tuesday, Marketbeat reports. The firm set a buy rating and a $33.00 price target on the stock. The Goldman Sachs Groups price ...

Sagimet Biosciences Inc. Series A (NASDAQ:SGMT) Receives New Coverage from Analysts at The Goldman Sachs Group

TD Cowen assumed coverage on shares of Sagimet Biosciences Inc. Series A (NASDAQ:SGMT Get Free Report) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set an outperform rating on the stock. SGMT has been the subject of several other research reports. Piper Sandler...

TD Cowen Initiates Coverage on Sagimet Biosciences Inc. Series A (NASDAQ:SGMT)

JMP Securities began coverage on shares of Sagimet Biosciences Inc. Series A (NASDAQ:SGMT Get Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The brokerage set an outperform rating and a $30.00 price target on the stock. JMP Securities price objective points to a potential ...

JMP Securities Initiates Coverage on Sagimet Biosciences Inc. Series A (NASDAQ:SGMT)

TD Cowen assumed coverage on shares of Sagimet Biosciences Inc. Series A (NASDAQ:SGMT  Get Free Report) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set an outperform rating on the stock. SGMT has been the subject of several other research ...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Watchers	61
52-Wk Low	$9.53
52-Wk High	$18.33

Market Cap	$207.78M
Volume (M)	134,091.00
52-Wk High	$18.33
52-Wk Low	$9.53

SGMT Sagimet Biosciences Inc

About

Feed

News

Fundamentals